AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23084093
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)
Trial: 20036117
Drug: CMF (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (oral cyclophosphamide, intravenous methotrexate and 5‐fluorouracil)
Trial: 18677165
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical exercise (45 min) at school
Trial: 12585827
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy (6 million U three times weekly for 48 weeks)
Trial: 1928034
Drug: Omnipaque (non-ionic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnipaque (non-ionic, iso-osmolar contrast agent)
Trial: 1928034
Drug: Hexabrix (ionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexabrix (ionic contrast agent)
Trial: 1928034
Drug: Hypaque (ionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypaque (ionic contrast agent)
Trial: 7042068
Drug: Chemotherapy (DTIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (DTIC 250 mg/M2 daily x 5 days + actinomycin-D 2 mg/M2 on day 1 every 3-4 weeks)
Trial: 7042068
Drug: Chemoimmunotherapy (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (same chemotherapy regimen + C. parvum 2 mg/M2 I.V. daily for 14 days before every third cycle and on days 7 and 14 of each cycle)
Trial: 31331579
Drug: Shiatsu therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shiatsu therapy in addition to standard care
Trial: 24886541
Drug: Telaprevir monotherapy
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir monotherapy (T arm)
Trial: 24886541
Drug: Telaprevir in
RxNorm normalized name: Product containing telaprevir in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir in combination with peginterferon/ribavirin (TPR arm)
Trial: 24886541
Drug: Telaprevir monotherapy
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir monotherapy (T arm) and TPR arm
Trial: 23206461
Drug: Preincisional parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Preincisional parecoxib (40 mg intravenously before skin incision)
Trial: 23206461
Drug: Postincisional parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Postincisional parecoxib (40 mg intravenously after skin incision)
Trial: 18586901
Drug: Standard photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard photodynamic therapy (sPDT) + 4 mg intravitreal triamcinolone (IVTA)
Trial: 18586901
Drug: Reduced fluence
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced fluence photodynamic therapy (rPDT) + 4 mg intravitreal triamcinolone (IVTA)
Trial: 12189542
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg m(‐2) i.v. day 1 and gemcitabine 1000 mg m(‐2) i.v. days 1, 8, and 15 of a 28 day cycle for a maximum of six cycles
Trial: 12189542
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and gemcitabine treatment
Trial: 10365742
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and No Heparin
Trial: 7621684
Drug: Levonorgestrel (LNG)‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (LNG)‐releasing subdermal implants (Norplant)
Trial: 7621684
Drug: Combined monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined monthly injectable contraceptives (50mg NET‐EN and 5mg estradiol valerate)
Trial: 7621684
Drug: Combined low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined low‐dose oral pills (triphasic and monophasic)
Trial: 2137076
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nebulized salbutamol followed by 0.5 mg ipratropium
Trial: 2137076
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs administered together followed by nebulized saline
Trial: 7003572
Drug: Meptazinol 100
RxNorm normalized name: meptazinol 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 100 mg orally
Trial: 7003572
Drug: Pentazocine 25
RxNorm normalized name: pentazocine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 25 mg orally
Trial: 30536589
Drug: GSK3342830 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3342830 (single intravenous doses ranging from 250 to 6000 mg)
Trial: 30536589
Drug: GSK3342830 (repeat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3342830 (repeat intravenous infusions 3 times a day)
Trial: 30536589
Drug: GSK3342830 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3342830 (multiple doses)
Trial: 30413184
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of varlilumab plus rituximab
Trial: 18924648
Drug: TDF/FTC/EFV regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC/EFV regimen (1 pill once a day)
Trial: 15804873
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) treatment in combination with buprenorphine (BUP)
Trial: 15804873
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) treatment in combination with methadone (Meth)
Trial: 8986585
Drug: Earles' balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earles' balanced salt solution supplemented with 15% preovulatory serum (control)
Trial: 30500116
Drug: Rifabutin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (300 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Trial: 30500116
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Trial: 23090528
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for mild GDM (397 women)
Trial: 17156141
Drug: Sulfate supplements
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfate supplements
Trial: 17156141
Drug: Sulfate supplements
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfate supplements with senna
Trial: 15860487
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 and etoposide 100 mg/m2 (arm A)
Trial: 15860487
Drug: Carboplatin AUC=6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin AUC=6 mg/ml min and paclitaxel 225 mg/m2 (arm B)
Trial: 10221068
Drug: bisoprolol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol 1.25 mg/day, progressively increased to a maximum of 10 mg/day
Trial: 8919833
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg i.v. 1 hour before induction of anaesthesia (Group A)
Trial: 8919833
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg i.v. 1 hour before end of surgery (Group B)
Trial: 2195929
Drug: Calcitonin 100
RxNorm normalized name: salmon calcitonin 100 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin 100 IU every other day plus 1 g of elemental calcium daily
Trial: 31909809
Drug: Walnut diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut diet (WD) [57-99 g/d walnuts, 7% SFAs, 16% PUFAs (2.7% ALA), 9% MUFAs]
Trial: 19603474
Drug: Additional meat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional meat intake (200 g pork fillet/day)
Trial: 17876463
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of spraying houses and animal pens, and eliminating infected dogs
Trial: 7815703
Drug: Midazolam 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2.5 mg
Trial: 6155338
Drug: Intranasal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccination with cold-adapted influenza A/HK/77 (H1N1) CR 35 recombinant virus
Trial: 25948064
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg/day for 6 weeks
Trial: 23949899
Drug: Mildronate injection
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate injection
Trial: 23949899
Drug: Cinepazide injection
RxNorm normalized name: cinepazide
DrugBank: Cinepazide (DB12123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinepazide injection (active-control)
Trial: 19266829
Drug: Propofol-MCT/LCT premixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-MCT/LCT premixed with 20 mg lignocaine (Group B)
Trial: 19266829
Drug: Propofol-LCT premixed
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-LCT premixed with 20 mg lignocaine (Group C)
Trial: 18664154
Drug: Topical 5-methyl
RxNorm normalized name: 5-methyl-8-hydroxyquinoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-methyl aminolevulinate cream applied for 1 hour before red light illumination
Trial: 18664154
Drug: Topical 5-methyl
RxNorm normalized name: 5-methyl-8-hydroxyquinoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-methyl aminolevulinate cream applied for 3 hours before red light illumination
Trial: 18664154
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment sides
Trial: 15355485
Drug: Topiramate (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100, 200, or 400 mg/day)
Trial: 2422778
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of PPS by intramuscular (I.M.) route (group I)
Trial: 2422778
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of PPS by intramuscular (I.M.) route (group II)
Trial: 2422778
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of PPS by subcutaneous (S.C.) route (group III)
Trial: 2422778
Drug: PPS administration
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPS administration
Trial: 11152033
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 0.65-1.0 mg x kg(-1)
Trial: 11152033
Drug: Paracetamol 13-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 13-20 mg x kg(-1)
Trial: 25027552
Drug: docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel plus cisplatin (20mg/m2/week) with concurrent radiotherapy (54Gy in 30 fractions)
Trial: 25027552
Drug: docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel plus 5-fluorouracil with concurrent radiotherapy
Trial: 22551208
Drug: Diflunisal, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal, a non-steroidal anti-inflammatory drug (NSAID)
Trial: 20206069
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 704 mg orally twice daily (NAC group, n=15)
Trial: 20206069
Drug: Aminophylline 250
RxNorm normalized name: aminophylline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 250 mg intravenously 30 min before CAG and/or PCI (aminophylline group, n=15)
Trial: 17633369
Drug: Panlongqi Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panlongqi Tablet (PLQ) in addition to NSAID and sulfasalazine (SSZ)
Trial: 16055815
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment (assertive community treatment, psychoeducational multi-family groups, social skills training)
Trial: 12170046
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml intravenous saline (Control)
Trial: 10525023
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment based on ductal flow pattern assessment (ECHO group)
Trial: 10525023
Drug: Conventional indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional indomethacin treatment (protocol group)
Trial: 1689934
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg daily
Trial: 1689934
Drug: Hydrochlorothiazide +
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide + Amiloride 5 mg
Trial: 26393373
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy (LTOT) prescribed for 15 hours per day including overnight hours
Trial: 9390662
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (5 g PO b.i.d. x 14 days -> 2 g PO b.i.d. x 7 days)
Trial: 7970099
Drug: Low-dose OKT3
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OKT3 induction therapy (0.5 mg OKT3 twice daily for 10 days)
Trial: 7970099
Drug: Low-dose OKT3
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OKT3 induction therapy
Trial: 2885650
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus pulsed ultrasound given weekly
Trial: 2885650
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (paste impregnated bandage and a self‐adhesive elastic bandage)
Trial: 21303311
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) at a dose of 200 mcg once daily for eight weeks after RF application
Trial: 10678137
Drug: Huperzine-A in
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine-A in capsules (4 capsules of Hup, each contains 50 micrograms)
Trial: 10678137
Drug: Huperzine-A in
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine-A in tablets (4 tablets of Hup, each contains 50 micrograms)
Trial: 10678137
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 tablets of placebo in capsule group and 4 capsules of placebo in tablet group)
Trial: 1503068
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg pyridoxine (PN)-HCl/d supplementation for mothers
Trial: 1503068
Drug: 27 mg
RxNorm normalized name: aspirin 227 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27 mg pyridoxine (PN)-HCl/d supplementation for mothers
Trial: 1503068
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg PN-HCl/d supplementation for infants of 2 mg/d supplemented mothers
Trial: 6299652
Drug: Griseofulvin 250
RxNorm normalized name: griseofulvin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 250 mg daily
Trial: 23866179
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg, 75 mg for pre-treated patients)
Trial: 15492353
Drug: Risperidone (0.01-0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.01-0.06 mg/kg/day, mean dosage: 0.04 mg/kg/day)
Trial: 10094445
Drug: Dexamethasone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.15 mg/kg per 6 h for 4 days)
Trial: 10094445
Drug: Control (antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antibiotics alone)
Trial: 6548926
Drug: Almax (6-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almax (6-8 g/d)
Trial: 6548926
Drug: Almax (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almax (4 g/d) with antisecretory drugs (cimetidine or ranitidine)
Trial: 6548926
Drug: Almax (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almax (lower doses)
Trial: 30005707
Drug: Active acupuncture
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active acupuncture group receiving standardized 30-min real acupuncture treatment for a total of 16 sessions on top of standard routine care.
Trial: 18371137
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FeCarb) - maximum 1,000 mg iron per infusion at 1-week intervals until total iron deficit reached
Trial: 18371137
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate (FeSulf) - 100 mg b.i.d. for 12 weeks
Trial: 10584678
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch containing 35 mg nicotine
Trial: 1826594
Drug: Teicoplanin at
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin at 6 mg/kg every 12 h for three doses, then 6 mg/kg every 24 h
Trial: 1826594
Drug: Vancomycin at
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin at 15 mg/kg every 12 h
Trial: 6961760
Drug: Labetalol (667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (667 mg daily)
Trial: 6961760
Drug: Propranolol (129
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (129 mg daily)
Trial: 6961760
Drug: Labetalol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (400 mg single oral dose)
Trial: 28687934
Drug: KGB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KGB and AG (6 g of fibre from KGB and 3 g of AG)
Trial: 19605879
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing plus oral health education
Trial: 17238881
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg x kg(‐1)
Trial: 11240084
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate immediate release (MSIR)
Trial: 799991
Drug: Ibuprofen 1600
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1600 mg/day
Trial: 28232973
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral health intervention (spoken)
Trial: 26390092
Drug: Control injection
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injection of excipient dosing in the contralateral leg
Trial: 23499204
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G sodium and gentamicin
Trial: 14681343
Drug: Nanocrystal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nanocrystal budesonide 0.5 mg
Trial: 14681343
Drug: Nanocrystal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nanocrystal budesonide 1.0 mg
Trial: 14681343
Drug: Pulmicort Respules
RxNorm normalized name: Pulmicort Respules
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort Respules 0.5 mg
Trial: 3513080
Drug: Cimetidine/pyrilamine eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine/pyrilamine eyedrops (combination treatment)
Trial: 29848153
Drug: All biologics
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All biologics
Trial: 25028536
Drug: Nanocrystal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocrystal formulation of megestrol acetate (625 mg/5 mL) in fasting state
Trial: 25028536
Drug: Nanocrystal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocrystal formulation of megestrol acetate (625 mg/5 mL) in fed state